Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder

Clinical Pharmacokinetics

Volumn 40, Issue 10, 2001, Pages 753-772

  Markowitz, John S ^a   Patrick, Kennerly S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMITRIPTYLINE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CLONIDINE; DEXAMPHETAMINE; GABAPENTIN; GUANETHIDINE; GUANFACINE; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PEMOLINE; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; PRIMIDONE; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROIC ACID;

ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0034758620     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140100-00004     Document Type: Review

References (158)

1. Attention deficit disorder: A review of the past 10 years
2. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder
3. Attention deficit hyperactivity disorder: Advances in cognitive, neurobiological, and genetic research
4. Attention-deficit/hyperactivity disorder and comorbidity
5. Treatment of attention-deficit-hyperactivity disorder
6. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents
7. Methylphenidate: US and European views converging?
8. Pharmacotherapy of attention-deficit hyperactivity across the life cycle
9. Neurobiology of attention-deficit hyperactivity disorder
10. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response
11. Alternative (nonstimulant) medications in the treatment of attention-deficit/hyperactivity disorder in children
12. Behavior of chidren receiving benzedrine
13. Hyperactivity: Presence and relationship with conduct disorder
14. Combined pharmacotherapy in children and adolescents in a residential treatment center
15. Combined pharmacotherapy: An emerging trend in pediatric psychopharmacology
16. Drug interactions with psychostimulants
17. Treatment of attention-deficit hyperactivity disorder
18. Pharmacokinetics and actions of methylphenidate
19. Enantioselective gas chromatographic-negative ion chemical ionization mass spectrometry for methylphenidate in human plasma
20. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder: A review
21. Gas chromatographic-mass spectrometric analysis of methylphenidate and p-hydroxymethylphenidate using deuterated internal standards
22. The more frequent diagnosis of attention deficit-hyperactivity disorder
23. Pharmacology of the enantiomers of threo-methylphenidate
24. Conformation analysis of methylphenidate and its structural relationship to other dopamine reuptake blockers such as CFT
25. Is methylphenidate like cocaine?
26. Anti-hyperactivity medication: Methylphenidate and amphetamine
27. Molecular, functional and biochemical characteristics of the dopamine transporter: Regional differences and clinical relevance
28. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder
29. Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia
30. Enantioselective behavioral effects of threo-methylphenidate in rats
31. Psychotropics and kids
32. Synthesis and pharmacology of hydroxylated metabolites of methylphenidate
33. Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid
34. Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability
35. Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans
36. A study of methylphenidate in man with respect to its major metabolite
37. Pharmacokinetics of methylphenidate in man, rat and monkey
38. Single-and multiple-dose pharmacokinetics of oral once-a-day osmotic controlled-release OROS7 (methylphenidate HCl) formulation
39. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic controlled-release oral delivery system
40. Disposition an metabolism of methylphenidate in dog and man
41. 14C: Studies in man and animals
42. Development of enantioselective gas chromatographic quantitation assay for dl-threo-methylphenidate in biological fluids
43. Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers
44. Liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry enantiomeric separation of dl-threo-methylphenidate, (Ritalin®) using a macrocyclic antibiotic as the chiral selector
45. Differences in plasma concentrations of the D- and L-threo methylphenidate enantiomers in responding and non-responding children with attention-deficit hyperactivity disorder
46. Detection of the novel metabolite ethylphenidate following methylphenidate overdose with alcohol co-ingestion
47. Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and alcohol
48. Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine
49. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine
50. Inhibition by ethanol of the metabolism of cocaine to benzoylecgonine and ecgonine methyl ester in mouse and human liver
51. Single dose methylphenidate pharmacokinetics in CYP 2D6 extensive and poor metabolizers
52. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dexamfetamine, and pemoline
53. A comparison of Ritalin and Adderall: Efficacy and time-course in children with attention-deficit/hyperactivity disorder
54. Levamphetamine vs. dextroamphetamine in minimal brain dysfunction
55. Drug interaction with brain biogenic amines and the effects of amphetamine isomers on locomotor activity
56. Methylphenidate, dextroamphetamine and levamphetamine
57. Kinetics salivary excretion of amphetamine isomers, and effect of urinary pH
58. Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats
59. Amphetamine: Effects on catecholamine systems and behavior
60. Dopamine and norepinephrine uptake by rat brain synaptosomes: Relative potencies of l and d amphetamine and amantidine
61. The metabolic fate of amphetamine in man and other species
62. Effect of metabolism on the response to dopamine agonists and antagonists
63. Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkyl-amphetamines and their 4-methoxylated derivatives
64. Interactions of amphetamine analogs with human liver CYP2D6
65. Quinidine inhibits in vivo metabolism of amphetamine in rats: Impact upon correlation between GC/MS and immunoassay findings in rat urine
66. Effect of CYP2D1 inhibition on the behavioral effects of D-amphetamine
67. N-Oxidation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (Form 3): Role in bioactivation and detoxification
68. Efficacy and safety of methylphenidate and pemoline in children with attention deficit hyperactivity disorder
69. Pemoline-associated hepatic injury
70. Pharmacokinetics of pemoline in plasma, saliva, and urine following oral administration
71. Oral pemoline kinetics in hyperactive children
72. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine
73. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver
74. Inhibition of imipramine metabolism by methylphenidate
75. A potential clinical use of methylphenidate with tricyclic antidepressants
76. Clinical and metabolic studies with imipramine in man
77. Concomitant imipramine and methylphenidate administration: A case report
78. Desipramine and methylphenidate combination treatment for depression: Case report
79. Side effects of methylphenidate and desipramine alone and in combination in children
80. Hypertensive episodes after adding methylphenidate (Ritalin) to tricyclic antidepressants
81. Combined methylphenidate and imipramine complication
82. Polypharmacy interactions
83. The antidepressant response to tricyclics is accelerated with the adjunctive use of methylphenidate
84. Suspected adverse methylphenidate-imipramine interactions in children
85. Absence of effect of stimulants on the pharmacokinetics of desipramine in children
86. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression
87. Toxic reactions to tranylcypromine
88. The dangers of some antidepressant drugs
89. Death after combined dextroamphetamine and phenelzine
90. Severe hyperexia due to tranylcypromine-amphetamine toxicity
91. CNS stimulant potentiation of monoamine oxidase inhibitors in the treatment of depression
92. Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: A review of published experience
93. The new antidepressants-selective serotonin reuptake inhibitors
94. Metabolism and pharmacokinetics of serotonin selective reuptake inhibitors
95. Sertraline with methylphenidate in an ICU patient
96. Medication-induced seizures
97. Fluoxetine and methylphenidate combination for treatment of attention deficit disorder and comorbid depressive disorder
98. Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: A case series
99. Methylphenidate augmentation of serotonin selective reuptake inhibitors: A case series
100. Treatment of a refractory depression with a combination of fluoxetine and d-amphetamine
101. Augmenting fluoxetine with dextroamphetamine to treat refractory depression
102. The potentiating effect of sertraline and fluoxetine on amphetamine-induced locomotor activity is not mediated by serotonin
103. Acute fluoxetine treatment potentiates amphetamine hyperactivity and amphetamine-induced nucleus acumbens dopamine release: Possible pharmacokinetic interaction
104. Subchronic fluoxetine treatment induces a transient potentiation of amphetamine-induced hyperlocomotion: Possible pharmacokinetic interaction
105. Methylphenidate interaction with both anticonvulsants and ethyl biscoumacetate
106. Possible phenytoin-methylphenidate interaction
107. Drug interaction: Effects of methylphenidate on the disposition of diphenylhydantoin in man
108. Effect of methylphenidate on plasma anticonvulsant levels
109. Epilepsy and attention deficit disorder: Is methylphenidate safe and effective?
110. Adverse response to methylphenidate in combination with valproic acid
111. Extreme reduction of methylphenidate levels by carbamazepine
112. Carbamazepine and methylphenidate in ADHD
113. Carbamazepine and methylphenidate
114. Methylphenidate, dextroamphetamine, and levoamphetamine: Effects on schizophrenic symptoms
115. Haloperidol and lithium blocking of the mood response to intravenous methylphenidate
116. The action of stimulant medication in attention deficit disorder with hyperactivity: Dopaminergic, noradrenergic, or both?
117. Does haloperidol block methylphenidate? Motivation or attention?
118. The effect of the dopamine receptor blocking drug pimozide on the stimulant and anorectic actions of dextroamphetamine in man
119. Comparative effects of methylphenidate and thioridazine in hyperkinetic children
120. 2 adrenergic agonists: Neurochemistry, efficacy, and clinical guidelines for use in children
121. Combining methylphenidate and clonidine: Pharmacologic questions and news reports about sudden death
122. Combining methylphenidate and clonidine: The role of post-marketing surveillance
123. Apilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder
124. Clonidine in the treatment of ADHD: Questions about safety and efficacy
125. Possible changes in noradrenergic receptor sensitivity following methylphenidate treatment: Growth hormone and MHPG response to clonidine in children with attention deficit disorder with hyperactivity
126. Antagonism of adrenergic neuron blockade in hypertensive subjects
127. Antagonism of the adrenergic neurone blocking action of guanethidine by certain antidepressant and antihistamine drugs
128. Concurrent therapy with d-amphetamine and adrenergic drugs
129. Effect of sympathomimetic amines on the blocking action of guanethidine, bretylium and xylocholine
130. The effect of methylphenidate and prolintane on the metabolism of ethylbiscoumacetate
131. Further studies of the inhibition of drug metabolism by methylphenidate
132. Studies of the inhibition of drug metabolism by methylphenidate
133. Inhibition of the metabolism of phenylbutazone by methylphenidate in man
134. Urinary excretion kinetics of amphetamine in man
135. Influence of urinary pH on excretion of amphetamine
136. A kinetic study of the hydrolysis of methyl dl-α-phenyl-2-piperidylacetate
137. Fatality resulting from methylphenidate overdose
138. The gastric secretion of drugs: A pH partition hypothesis
139. Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents
140. Antihypertensive drugs interacting with α- and β-adrenoceptors: A review of basic pharmacology
141. Guanfacine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of hypertension
142. Interaction between clonidine and desipramine in man
143. Hypertensive crisis induced by interaction of clonidine with imipramine
144. Interactions between centrally acting antihypertensive drugs and tricyclic antidepressants
145. Antagonism of antihypertensive effects of guanfacine by tricyclic antidepressants
146. Interactions between antipsychotic and antihypertensive drugs
147. Rapid clonidine withdrawal with blood pressure overshoot exaggerated by beta-blockade
148. Withdrawal of anti-hypertensive therapy. Hypertensive crisis in renovascular hypertension
149. Fatal rebound hypertension after abrupt withdrawal of clonidine and propranolol
150. Clonidine and propranolol paradoxical hypertension
151. Interaction between beta-blockers and clonidine
152. Interaction between clonidine and cyclosporine A
153. P-glycoprotein
154. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine
155. Adverse interaction between clonidine and verapamil
156. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil
157. Increased plasma valproate concentrations when coadministered with guanfacine